Respiratory Medicine 1998: Vol 92 Index

25 Pages·1998·7.2 MB·English

RESPIRATORY
Subject Index
MEDICINE
Editorials, Letters to the Editor, Case Reports and Short Reports are indicated by (E), (L), (CR) and
(SR) after the page numbers, respectively. S.A. = Supplement A; S.B. = Supplement B
A-a egfrfeacdtise notn v1a9l1u-e7 in asthma, bronchoalveolar lava cgS—s e aammyblrooixdools isc,h arraeacctteirviez,a tiino nM yicno baanctit-eorxiiudman t sitmhiaeer appyu l6m0o9n-a2r3y
N-acetylcysteine infection 123-4 (CR)
characterization in anti-oxidant therapy 609-23 anaesthesia
inhibition of IL-la-induced IL-8 secretion by bronchial local, pulse oximetry at fibreoptic bronchoscopy 532
epithelial cells 512-15 and sedation practice in coronary artery bypass surgery,
acetylsalicylic acid-induced asthma, inhalation challenge ICU and hospital stay length and 1066-70
378-84 angiotensin-converting enzyme genetic polymorphism in
acupuncture in treatment of stable asthma 1143-5 asthma 1305-10
adenoma, pleomorphic, and severe tracheal obstruction anti-inflammatory
889-91 (CR) effect in COPD subgroups 1259-64
adrenal function, effects of beclomethasone dipropionate treatment effect on bronchial asthma 547-9
compared with budesonide (S.B.) 2-45 anti-Jo-1 antibodies, pulmonary vasculitis with 986-8 (CR)
adult respiratory distress syndrome, idiopathic bronchiolitis anti-oxidant therapy 609-23
obliterans with pneumonia 884-6 (CR) effect in COPD subgroups 1259-64
aerosol, hypo-osmolar, induction of hyperventilation in antibiotics effect on lung mucociliary clearance during
chronic non-asthmatic rhinitics 9-13 COPD exacerbation 442-7
air pollution and asthma-related emergency visits, neural arterial blood gases during dialysis in pressure support
network study of relationship between 1199-202 ventilation 53440
airways asbestos pleural disease, benign, finger clubbing in 691
non-adrenergic, non—cholinergic function 461-6 (SR)
obstruction, chronic upper, pulmonary edema following aspergillosis
1174-6 (CR) allergic bronchopulmonary, therapy with itraconazole
responsiveness, effect of influenza vaccination in asthma 118-19
1010-11 pulmonary, in insulin-dependent diabetic 972-5 (CR)
see also chronic obstructive airways disease; obstructive Assess peak flow meter 505-11
airways disease; peripheral airways asthma
alglucerase treatment of type | Gaucher disease with pul- ACE genetic polymorphism 1305-10
monary involvement 1370-2 (CR) acute childhood, prednisolone in 541-6
allergen exposure, low-dose repeated, to induce experimen- acute severe, treated by mechanical ventilation 716-21
tal exacerbation of asthma 1223-30 ASA-induced, inhalation challenge 378-84
allergic bronchopulmonary aspergillosis therapy with itra- beclomethasone dipropionate comparison with budeso-
conazole 118-19 CR) nide (S.B.) 2-45
allergic rhinitis delivery improvement with hydrofluoroalkane-134a
effect of topical steroids on nasal nitric oxide production (S.A.) 3-39
558-61 best function prediction of mortality 1274-80
methacholine response characteristics 88-94 beta,-agonists in dry powder inhaler 167—72
allergy bronchial, diffuse pulmonary ossification and recurrent
in childhood, effect of socioeconomic status, birth order spontaneous pneumothorax 887-9 (CR)
and maternal smoking on 1237-44 epidemiology in Turkey 792-3 (L)
self-reported, gene mapping in families 1281-8 nasal inflammation and anti-inflammation treatment
type 1, and asthma in Swedish children 316-24 effects 547-9
alpha-l-antitrypsin deficiency bronchoalveolar lavage effects on PaO,, A-a gradient
national registry in Spain 1181-7 value and bronchoconstriction 191-7
PiSZ, geographical distribution in Europe 367-77 risk bronchoconstriction in relation to methacholine bron-
factor in pulmonary emphysema 241-5 chial responsiveness in 308-15
alveolar compartment non-involvement in inflammatory budesonide as nebulizer suspension vs metered dose
response in non-small cell lung cancer 76-83 inhaler 44-49
alveolar macrophages once-daily 421—5
budesonide and terbutaline effects on phagocytosis 162-6 cardiorespiratory response to submaximal exercise fol-
in sarcoidosis 126-39 lowing salbutamol and salmeterol 1053-8
smoking and interleukin-8 secretion by 922-7 in children, salmeterol vs “as required’ salbutamol 292-9
alveolitis chronic severe, peripheral airways obstruction on CT
evaluation by IL-8 in BAL cells in idiopathic pulmonary 448-53
fibrosis 338-44 clinic, nurse-run 264—7
parasitic 1—3 corticosteroids pharmacology 385—94
Supplement B July 1998
Foreword: Guest Editorial
R. Dahil
Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide
A. R. Boobis
Efficacy of inhaled beclomethasone dipropionate and budesonide in the treatment of asthma
D. R. Webb
Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, skin changes and cataract formation
R. G. Diuhy
Comparative review of the effects of inhaled beclomethasone dipropionate and budesonide on bone
M. D’Souza
Effect of inhaled beclomethasone dipropionate and budesonide on growth in children with asthma
D. B. Allen
diagnosis, rapid dosimetric methacholine challenge 32-39 delivery improvement with hydrofluoroalkane-134a
in elderly 573-7 (S.A.) 3-39
evaluation of electronic hand-held spirometer 1177-80 vs ketotifen and disodium cromoglycate effects on bron-
exercise-induced, gastro—oesophageal reflux and 1071—5 chial mucosa and asthma symptoms 942-50
experimental exacerbation following low-dose repeated beta,-agonists in dry powder inhaler for acute asthma
allergen exposure 1223-30 167-72
fluticasone propionate therapy 95—104 BIPAP device for obstructive sleep apnoea syndrome 820-7
follow-up rates following casualty attendance, hospital birth order and maternal smoking effect on childhood
primary care communication and 289-91 allergy 1237-44
formoterol vs salbutamol onset of action in reversing blindness from bronchial artery embolization 983-6 (CR)
methacholine-induced bronchoconstriction 1346-51 blood
gas compression profile during forced expiration in 173-7 eosinophil and monocyte counts related to smoking and
guidelines 1046-52 lung function 63-69
health status measurement 1207-14 gases in non-smoking women with chronic liver disease
home nebulizers for adults 624-7 57-62
hospitalisation rates in Black and ethnic minority com- transcutaneous monitoring 584-7
munities 642-8 bone, effects of beclomethasone dipropionate comparison
survival of middle-age patients 1256 (L) with budesonide (S.B.) 2-45
influenza vaccination effect on airway responsiveness in Book Reviews
1010-11 Clinical and biological basis of lung cancer prevention 1373
inhaler comparison 105-10, 111-17 Peak flow measurement. An illustrated guide 365
Breathe Right™ effects on snoring 1076-8
intensive vs conventional patient education and super-
vision for self-management 300-7 breathing, sleep-disordered, comparison in Asians and
Caucasians 843-8
leukotriene antagonism in 795—809
breathlessness in COPD, salmeterol vs ipratropium bro-
lignocaine inhalation effect on FEV, and _ bronchial
mide effects on 1116-21
reactivity in 1359-63
British Asthma Guidelines 1046-52
long-term therapy with salmeterol vs _ slow-release
bromocriptine, pleuropulmonary disease as side-effect of
theophylline 683-90
treatment with 1172-4 (CR)
methacholine response characteristics 88-94
bronchial artery embolization, cortical blindness from
nebulizer therapy at home 1000-2
983-6 (CR)
non-adrenergic, non-cholinergic function of airways bronchial
461-6 aspirates and transbronchial biopsies, PCR for diagnosis
occupation, leukocyte counts in sputum 550-7 of smear-negative pulmonary TB 815-19
parallels with parasitic alveolitis 1—3 carcinoma, bronchoscopy and audit standards 1110-15
pulmonary function and symptoms 849-57 epithelial cells, glucocorticoid receptor mRNA levels in
recent-onset, work ability 729-34 COPD, role of glucocorticoids 1102-9
-related emergency visits and air pollution, neural net- N-acetylcystein inhibition of IL-la-induced IL-8 secre-
work study of relationship between 1199-202 tion by 512-15
-related prescribing patterns with corticosteroid inhaler epithelium, neutrophils infiltrating in COPD 863-70
devices 1352-8 hyperreactivity related to nitric oxide exhalation 908-13
salbutamol via Turbohaler vs metered-dose inhaler in in Sweden 480-7
325-30 without specific response to isocyanate in isocyanate-
salmeterol trials 777-82 induced asthma 1093-8
salmeterol vs theophylline 256—63 metastases in chondroblastic osteosarcoma 786-8 (CR)
salmeterol xinafoate 1302-4 (SR) mucosa; ketotifen vs disodium cromoglycate and beclom-
self-reported, gene mapping in families 1281-8 ethasone dipropionate effects on 942-50
self-treatment guidelines for adults 668-75 papilloma, solitary columnar 878-9 (CR)
severity marker relationship to exhaled nitric oxide reactivity in asthma, lignocaine inhalation effect on
908-13 1359-63
stable, acupuncture treatment 1143-5 bronchiolitis obliterans, idiopathic, with pneumonia in
steroid-dependent, management with methotrexate adult respiratory distress syndrome 884-6 (CR)
1059-65 bronchitic symptoms, obstructive sleep apnoea syndrome
survival in hospitalized population 568—72 symptoms related to 283-8
symptoms, ketotifen vs disodium cromoglycate and bronchitis
beclomethasone dipropionate effects on 942-50 acute, von Willebrand factor antigen plasma levels 395
in Turkish children 203-7 400
in young adulthood 1003-9 chronic, antibiotic choice and dosage regimen for exacer-
time trends and seasonal variation in tropical Singapore bations 895-901
345-50 (SR) bronchoalveolar lavage
type-1 allergy and related condition in Swedish children cells, in eosinophilic pneumonia 743-9
316-24 interleukin-8 expression to evaluate alveolitis in
idiopathic pulmonary fibrosis 338-44
beclomethasone dipropionate lavage effects on PaO,, A—a gradient value and broncho-
comparison with budesonide (S.B.) 2-45 constriction in asthma 191-7
enCEOSeNTeaaYAN arNeSn
fluid, hepatocyte growth factor measurement in pul- cholesterol levels to distinguish transudates from exudates
monary fibrosis 273-8 762-5
fluid, integrin expressions by mononuclear phagocytes chronic obstructive pulmonary disease (COPD)
in 1326-30 anti-oxidant and anti-inflammatory effects in subgroups
fluid, in lung cancer, cytokine fragment 19 as diagnos- 1259-64
tic marker in 766-71 C-reactive protein measurements 664-7
fluid, lymphocyte phenotype compared to DLCO corticosteroid treatment during oxygen therapy 50-56
impairment in systemic sclerosis 1295-301 EUROSCOP study 457-72
T cell receptor subsets of lymphocytes in pulmonary exacerbation, antibiotics effect on lung mucociliary clear-
TB 408-14 ance during 442-7
bronchoconstriction exercise test duration and dyspnea recovery time, effects
in asthma, bronchoalveolar lavage effects on 191-7 of oxygen breathing and repeat testing 735-8
methacholine-induced, salbutamol vs formoterol onset of training and recovery after exacerbation 1191-8
action in reversing 1346-51 Fas levels 993-9
in relation to methacholine bronchial responsiveness in FEV, value in screening for PaO, <7.3 kPa in patients
asthma 308-15 qualifying for long term O, therapy 1122-6
bronchodilation prediction and salbutamol early reversibil- glucocorticoid receptor mRNA levels in bronchial epi-
ity after salmeterol in COPD 1012-16 thelial cells, effect of glucocorticoids 1102-9
broncholithiasis 963-5 (CR) heart disease and 1256-7 (L)
bronchoscopy hospitalisation, survival of middle-age patients 1256 (L)
for bronchial carcinoma and audit standards 1110-15 hypoxia effect on renal hormonal balance in 1331-6
changes in oxygen saturation and transcutaneous carbon nebulizer therapy at home 1000-2
dioxide and oxygen levels during 739-42 neutrophils infiltrating bronchial epithelium in 863-70
fibreoptic, for diagnosis of smear-negative pulmonary TB NPPV and haemodynamic responses 331-7
815-19 oral corticosteroid effects on bronchodilator responses
lignocaine and monoethylglycinexylidide levels during 279-82
40-43 outcome following nocturnal non-invasive mechanical
pulse oximetry in local anaesthesia 532-7 ventilation 1215-22
budesonide predicting cognitive decline 527-33
in asthma, nebulizer suspension vs metered dose inhaler pulmonary function threshold for distinguishing
44-49 ventilatory- and nonventilatory-limited patients
comparison with beclomethasone dipropionate (S.B.) 1245-50
2-45 quality of life correlated with lung and muscle function
effects on phagocytosis in alveolar macrophages 162-6 221-7
nebulized, vs fluticasone propionate delivery via inhaler in elderly 1231-6
and Volumatic 111-17 salbutamol early reversibility and bronchodilation pre-
once-daily in asthma 421-5 diction after salmeterol in 1012-16
Burkholderia cepacia transmission and prevalence in cystic salmeterol vs ipratropium bromide effects on exercise
fibrosis 178-83 performance and breathlessness in 1116-21
vs oxitropium bromide as bronchodilators 354—7 (SR)
C-reactive protein measurements in COPD 664-7 screening with pulse oximetry for long-term domiciliary
Candida albicans, pulmonary mycetoma from 1079-80 oxygen need 1265-8
(CR) single breath vs re-breathing 7LCO 18-24
carbon monoxide level measurement with single-breath subjective fatigue and physiological variables 676-82
transfer factor 628-32 survival in hospitalized population 568—72
carcinoid, thymic, with mucinous stroma 880-2 (CR) tension-time index of inspiratory muscles 828-35
cardiac time course of respiratory decompensation 936-41
sarcoidosis, MRI imaging 697-9 (CR) ventilation in ICU outcome 156-61
surgery. positive end-expiratory pressure effect 858-62 vital prognosis following hospitalization 772-6
cardiorespiratory response to submaximal exercise follow- cognitive decline prediction in COPD 527-3
ing salbutamol and salmeterol in asthma 1053-8 congestive heart failure effect on pulmonary function
cat, effect on lung function in primary school children 1321-5
928-35 cortical blindness from bronchial artery embolization 983—6
cataract formation, effects of beclomethasone dipropionate (CR)
comparison with budesonide (S.B.) 2-45 corticosteroid
CD4 lymphocytopenia and meningitis with pulmonary inhaler devices, asthma-related prescribing patterns with
cryptococcoma in HIV-negative patient 120-2 (CR) 1352-8
CD4"* T-lymphocytopenia, miliary TB causing acute respir- oral, effects on bronchodilator responses in COPD
atory failure in 977-9 (CR) 279-82
cefamandol, early transition to oral therapy in community- pharmacology 385-94
acquired pneumonia 1032-9 treatment in COPD during oxygen therapy 50-56
chest cough, persistent, prescribing for 638-41
CT scans in lung endometriosis 876-7 (CR) CPAP therapy failure in obstructive sleep apnoea syndrome
radiography and TB case-finding in Australia 198-202 208-15
tube, curved 633-7 Cushing’s disease and TB 604-6 (CR)
cyclosporin A effect on inflammatory cytokine production submaximal, cardiorespiratory response in asthma fol-
by alveolar macrophages 722-8 lowing salbutamol and salmeterol 1053-8
cystic fibrosis test duration and dyspnea recovery time in COPD, effects
Burkholderia cepacia transmission and prevalence 178-83 of oxygen breathing and repeat testing 735-8
diabetic retinopathy in 871-2 training and recovery in COPD after exacerbation
epithelial cell damage from neutrophil-derived proteases 1191-8
in sputum 233-40
hypomagnesaemic tetany from i.v. tobramycin in 602-4 Fas levels in COPD 993-9
(CR) 7 fatigue, subjective, in COPD 676-82
lobectomy in 695-7 (CR) Felty’s syndrome, pulmonary veno-occlusive disease com-
nasal intermittent positive pressure ventilation 523-6 plicating 1089-91 (CR)
Nottingham Health Profile scores 268—72 FEV, value in COPD screening for PaO, <7.3 kPa in
Xanthomonas maltophila respiratory infection therapy in patients qualifying for long term O, therapy 1122-6
363-4 (CR) fibrosis in sarcoidosis 140-9
cytokine finger clubbing in malignant mesothelioma and benign
fragment 19 as diagnostic marker in bronchoalveolar asbestos pleural disease 691-2 (SR)
lavage fluid in lung cancer 766-71 fluticasone propionate
network in sarcoidosis 126-39 outcomes and cost-effectiveness audit 351—3 (SR)
production by alveolar macrophages, cyclosporin A therapy in asthma 95-104 delivery via inhaler and
effect 722-8 Volumatic vs nebulized budesonide 111-17
pro-inflammatory, compartmentalization in tuberculous forced spirometry, prediction equations in European popu-
pleurisy 14-17 lations 401-7
response, effect of hyperoxia 951-60 formoterol
efficacy in elderly with reversible obstructive airways
dermatomyositis disease 562-7
and small cell lung cancer of lung 601-2 (CR) inhalation, onset and duration of action of single doses
response to chemotherapy for non-small cell lung cancer 1017-21
788-90 (CR) vs salbutamol onset of action in reversing methacholine-
diabetes, pulmonary aspergillosis and 972—5 (CR) induced bronchoconstriction 1346-51
diabetic retinopathy in cystic fibrosis 871-2 vs salmeterol in reversible obstructive airways disease
diaphragm shortening during hypercapnia in rats 4-8 836-42
Diskus vs Turbuhaler“ 105-10 free radicals 609-23
disodium cromoglycate vs ketotifen and beclomethasone
dipropionate effects on bronchial mucosa and asthma gas compression profile during forced expiration in asthma
symptoms 942-50 and health 173-7
DLCO impairment compared to BALF lymphocyte pheno- gastro-oesophageal reflux
type in systemic sclerosis 1295-301 and exercise-induced asthma 1071-5
dyspnea recovery time following exercise testing in COPD, with haemoptysis and carinal erythematous lesion
effects of oxygen breathing and repeat testing 735-8 1251-2 (CR)
Gaucher disease, type 1, with pulmonary involvement,
ECG changes in obstructive sleep apnoea syndrome alglucerase treatment 1370-2 (CR)
25-27 gene mapping in families self-reporting asthma and allergy
electric baseboard heating effect on lung function in pri- 1281-8
mary school children 928-35 genetic polymorphism in asthma, ACE 1305-10
emphysema, lung volume reduction for, lung function and glucocorticoid
quality of life following increased elastic recoil after in asthma 385-94
653-8 receptor mRNA levels in bronchial epithelial cells in
empyema, salmonella, following splenic biopsy 968-9 (CR) COPD, effect of glucocorticoids 1102-9
endobronchial granulocyte transit time through lung, bimodal, deconvol-
non-Hodgkin’s lymphoma 975-7 (CR) ution analysis 1163-6 (SC)
secondaries occurrence 599-600 (SR) growth in children with asthma, effects of beclomethasone
eosinophil counts related to smoking and lung function dipropionate comparison with budesonide (S.B.) 2-45
63-69
epithelial cell haemopoietic progenitor cell transplantation, pulmonary
damage from neutrophil-derived proteases in cystic fibro- Langerhans’ cell histiocytosis following autologous
sis sputum 233-40 1253-5 (CR)
in sarcoidosis 126-39 haemoptysis with gastroesophageal reflux and carinal
EUROSOPC study on COPD 467-72 erythematous lesion 1251-2 (CR)
exercise haemosiderosis, idiopathic pulmonary 902
induced asthma, gastro-oesophageal reflux and 1071—5 health habits and illness behaviour 150—5
performance in COPD, salmeterol vs ipratropium bro- heart
mide effects on 1116-21 disease and COPD 1256-7 (L)
pulmonary rehabilitation programme effect on failure, congestive, nocturnal oxygen and hypercapnic
1146-54 ventilatory response 426-31
hepatocyte growth factor measurement in serum and bron- ketotifen vs disodium cromoglycate and beclomethasone
choalveolar lavage fluid in pulmonary fibrosis 273-8 dipropionate effects on bronchial mucosa and asthma
histiocytosis, pulmonary Langerhans’ cell, following symptoms 942-50
autologous haemopoietic progenitor cell transplanta- Kviem-Siltbach test 126-39
tion 1253-5 (CR)
HLA-DQBI! and HLA-DPBI genotypes in familial sar- lactate dehydrogenase to distinguish transudates from exu-
coidosis 649-52 dates 762-5
hospital stay following coronary artery bypass surgery, Langerhans’ cell histiocytosis, pulmonary, following
anaesthetic practice and 1066-70 autologous haemopoietic progenitor cell transplan-
house dust tation 1253-5 (CR)
mite exposure evaluation 1099-101 leukocyte counts in sputum in occupational asthma 550-7
swine, and levels of IL-1f and IL-1 receptor antagonist in leukotriene
peripheral blood 1022-7 antagonism in asthma and rhinitis 795-809
hydrofluoroalkane-134a, delivery improvement of beclom- D,/E, receptor antagonist for diffuse panbronchiolitis
ethasone dipropionate (S.A.) 3-39 1084-6 (CR)
hypercapnia in rats, diaphragm shortening and _intra- Light’s criteria vs biochemical parameters to distinguish
thoracic pressure during 4-8 transudates from exudates 762-5
hypercapnic respiratory failure, nasal intermittent positive lignocaine
pressure ventilation 523-6 inhalation effect on FEV, and bronchial reactivity in
hypercapnic ventilatory response in congestive heart failure asthma 1359-63
426-31 levels during fibreoptic bronchoscopy in local anaesthesia
hypersensitivity pneumonitis caused by cyclosporine 40-43
1368-70 (CR) liver disease, chronic, blood gases in non-smoking women
hypomagnesaemic tetany from i.v. tobramycin in cystic 57-72
fibrosis 602-4 (CR) lobectomy in cystic fibrosis 695-7 (CR)
hypoxia effect lung
on macrophage cytokine response 951-60 abscess with squamous epithelial lining 790-1 (CR)
on renal hormonal balance in COPD 1331-6 cancer, cytokine fragment 19 as diagnostic marker in
bronchoalveolar lavage fluid 766-71
ICl non small-cell, inflammatory response 76-83
stay following coronary artery bypass surgery, anaes- with malignant effusion, intrapleural paclitaxel for
thetic practice and 1066-70 473-9
ventilation outcome in COPD 156-61 response of dermatomyositis to chemotherapy for
illness behaviour, health habits and 150-5 788-90 (CR)
inflammatory bowel disease, lung function 516-22 small cell, dermatomyositis and 601—2 (CR)
influenza vaccination effect on airway responsiveness in deconvolution analysis of bimodal granulocyte transit
asthma 1010-11 time 1163-6 (SC)
inhaler disease hospitalization in early childhood 1003-9
interstitial, p53 protein overexpression 184-90
comparison 105-10, 111-17
in systemic sclerosis 1295-301
new powder, salbutamol bronchoprotection 578-83
obstructive, prevalence in Sweden 1337-45
integrin expressions by mononuclear phagocytes in periph-
see also chronic obstructive lung disease (COPD)
eral blood and BALF 1326-30
endometriosis, CT scans 876-7 (CR)
interleukin-1f and receptor antagonist levels in peripheral
function, eosinophil and monocyte counts related to
blood from swine house dust inhalation 1022-7
smoking and 63-69
interleukin-8
impairment, obstructive sleep apnoea syndrome symp-
expression in BAL cells to evaluate alveolitis in idio-
toms related to 283-8
pathic pulmonary fibrosis 338-44 improvement following increased elastic recoil after
secretion by alveolar macrophages, smoking and 922-7 lung volume reduction surgery in emphysema
by bronchial epithelial cells, N—acetylcystein inhibition 653-8
of IL-la-induced 512-15 in inflammatory bowel disease 516-22
interstitial lung diseases, p53 protein overexpression 184-90 lignocaine inhalation effect on FEV, and bronchial
intrathoracic pressure during hypercapnia in rats 4-8 reactivity in asthma 1359-63
IPPV in cystic fibrosis and hypercapnic respiratory failure measurements, prediction equations in European
523-6 populations 401-7
ipratropium bromide vs salmeterol effects on exercise per- of primary school children, domestic factors and
formance and breathlessness in COPD 1116-21 928-35
isocyanate-induced asthma, bronchial hyperresponsiveness quality of life in COPD correlation 221—7
without specific response to isocyanate in 1093-8 volumes, plethysmographic, prediction equations 454-60
itraconazole therapy of allergic bronchopulmonary reduction surgery in emphysema, improved lung func-
aspergillosis 118-19 tion and quality of life following increased elastic
recoil after 653-8
Jo-1 syndrome, pulmonary fibrosis in polymyositis in lymphocyte phenotype in BALF compared to DLCO
1167-9 (CR) impairment in systemic sclerosis 1295-301
lymphoma, large cell intravascular, pulmonary presentation neutrophil
of 1087-9 (CR) -derived proteases in cystic fibrosis sputum, damage to
lymphomatoid granulomatosis mimicking sarcoidosis epithelial cells 233-40
966-8 (CR) infiltrating bronchial epithelium in COPD 863-70
nitric oxide
macrolide antibiotics for diffuse panbronchiolitis 10846 exhaled, relationship to markers of asthma severity
(CR) 908-13
macrophage production, nasal, in perennial allergic rhinitis, effect of
alveolar, cyclosporin A effect on inflammatory cytokine topical steroids 558-61
production by 722-8 and respiratory system 701—15
smoking and interleukin-8 secretion by 922-7 Nocardia asteroides drug resistance in pulmonary nocardi-
budesonide and terbutaline effects on phagocytosis in osis 873-5 (CR)
162-6 non-Hodgkin’s lymphoma, endobronchial 975-7 (CR)
cytokine response, effect of hyperoxia 951-60
phenotype in sputum, smoking and 415~20 obstructive airways disease
in sarcoidosis 126-39 reversible, efficacy of formoterol in elderly 562
malignant mesothelioma, finger clubbing 691—2 (SR) formoterol vs salmeterol in 836-42
MDPI inhaler, salbutamol bronchoprotection 578-83 see also chronic obstructive airways disease
mechanical ventilation for acute severe asthma obstructive sleep apnoea syndrome
mediastinal nonseminomatous germ cell tumour 882-4 ambulatory diurnal sleep recording 216-20
(CR) appearance of central apnoea following auto-CP/
meningitis and CD4 lymphocytopenia with pulmonary 891-3 (CR)
cryptococcoma in HIV-negative patient 120-2 (CR) CPAP therapy failure in 208-15
methacholine ECG changes 25-27 nasal continuous positive airway
bronchial responsiveness in relation to cold air inhalation pressure treatment interruption 28-31
and exercise-induced bronchoconstriction in asthma hypopnoea number effect on therapy 1028-31
308-15 symptoms related to bronchitic symptoms or lung func-
challenge in asthma diagnostics 32-39 tion impairment 283-8
chloride, stability in solution, effect of pH 588-92 osteosarcoma, chondroblastic, endobronchial metastases in
induced bronchoconstriction, salbutamol vs formoterol 786-8 (CR)
onset of action in reversing 1346-51 oxitropium bromide
response characteristics in asthma, allergic rhinitis and effects on bronchodilator responses in COPD 279-82
healthy subjects 88-94 vs salmeterol as bronchodilators in COPD 354~7 (SR)
methotrexate, management of steroid-dependent asthma oxygen
1059-65 breathing effects, exercise test duration and dyspnea
Mini-Wright peak flow meter 505-11 recovery time in COPD 735-8
monocyte counts related to smoking and lung function levels during dialysis in pressure support ventilation
63-69 534-40
monoethylglycinexylidide levels during fibreoptic bron- need, COPD screening with pulse oximetry for long-term
choscopy in local anaesthesia 40-43 domiciliary 1265-8
mononuclear phagocytes integrin expressions in peripheral saturation changes in fibreoptic bronchoscopy 739-42
blood and BALF 1326-30 supply, concentrators in domiciliary situation 250-5
Morgan Transflow system 628-32 therapy in COPD, corticosteroid treatment during 50—56
mucociliary clearance, antibiotics effects during OPCD and FEV, value in COPD screening for PaO,<7.3 kPa
exacerbation 442-7 1122-6
muscle function, quality of life in COPD correlation 221—7 long-term, characteristics and complaints of patients
mycetoma, pulmonary, from Candida albicans 1079-80 70-75
(CR) liquid vs oxygen concentrators or compressed gas
Mycobacterium simiae pulmonary infection, reactive amyl- cylinders, patient characteristics 84-87
oidosis in 123-4 (CR) nocturnal, in congestive heart failure 426-31
Mycobacterium vaccae safety and outcome measures 597-8 patient compliance improvement 1203-6
(SR) transcutaneous level changes in fibreoptic bronchoscopy
739-42
nasal continuous positive airway pressure
for obstructive sleep apnoea syndrome 820-7 p53 protein overexpression in interstitial lung diseases
treatment interruption in obstructive sleep apnoea 28-31 184-90
nasal inflammation effect on bronchial asthma 547-9 paclitaxel, intrapleural, for non small-cell lung cancer with
nasal intermittent positive pressure ventilation in cystic malignant effusions 473-9
fibrosis and hypercapnic respiratory failure 523—6 panbronchiolitis, diffuse, treated with low-dose macrolide
nebulizer antibiotics and leukotriene D,/E, receptor antagonist
therapy at home 1000-2 1084-6 (CR)
in adult asthma 624-7 PaO, in asthma, bronchoalveolar lavage effects on 191
neural network study of relationship between air pollution papilloma, bronchial solitary columnar 787—9 (CR)
and asthma-related emergency visits 1199-202 parasitic alveolitis parallels with asthma 1-3
patient cryptococcoma with CD4 lymphocytopenia and menin-
behaviour and health habits 150-5 gitis in HIV-negative patient 120-2 (CR)
compliance, diary compared to monitor recording disease, domiciliary non-invasive ventilation in elderly
1188-90 patients 1311-20
improvement with long-term oxygen therapy following edema following chronic upper airway obstruction
formal assessment and training 1203-6 1174-6 (CR)
PCR for diagnosis of smear-negative pulmonary TB 815-19 emphysema, alpha,-antitrypsin deficiency PiSZ, risk
peak flow meters compared 505-11 factor in 241-5
PEF diurnal variability related to nitric oxide exhalation eosinophilia, tropical, pathogenesis 1—3
908-13 fibrosis, hepatocyte growth factor measurement in serum
peripheral airways obstruction on CT in chronic severe and BAL 273-8
asthma 448-53 idiopathic, interleukin-8 expression in BAL cells to
phagocytosis in alveolar macrophages, budesonide and evaluate alveolitis in 338-44
terbutaline effects 162-6 in polymyositis with the Jo-1 syndrome 1167-9 (CR)
plethysmographic lung volumes, prediction equations function in asthma 849-57
454-60 effect of long-standing heart failure 1 321-5
pleural laboratories re-audit 1155-62
biopsy vs pleuroscopy in malignant effusion or tubercu- threshold for distinguishing ventilatory- and
lous pleurisy 488-92 nonventilatory-limited patients with airflow
obstruction 1245-50
brushing, closed percutaneous 659-63
haemosiderosis, idiopathic 902—7
disease from asbestos, finger clubbing in 691—2 (SR)
infarction revealing pulmonary Takayasu’s arteritis
effusion, Light’s criteria vs biochemical parameters to
969-71 (CR)
distinguish transudates from exudates 762-5
infection, reactive amyloidosis in 12304 (CR)
malignant, pleurodesis with small percutaneous cath-
infiltrates, migratory 1081-4 (CR)
eter 593-6
involvement with type 1 Gaucher disease, alglucerase
use of curved chest tube drainage 633-7
treatment 1370-2 (CR)
mass developing following talc pleurodesis 358-9 (CR)
Langerhans’ cell histiocytosis following autologous hae-
pleurisy, tuberculous, pro-inflammatory cytokine compart-
mopoietic progenitor cell transplantation 1253-5
mentalization 14-17
(CR)
pleuropulmonary disease as side-effect of treatment with mycetoma from Candida albicans 1079-80 (CR)
bromocriptine 1172-4 (CR)
nocardiosis, drug resistance in 873-5 (CR)
pneumonia ossification, diffuse, in bronchial asthma 887-9 (CR)
bacterial, rhabdomyolysis and 359-62 (CR) presentation of intravascular large cell lymphoma 1087-9
community-acquired, early transition to oral antibiotic (CR)
therapy 1032-9 rehabilitation programme effect on exercise performance
time course of symptom resolution 1137-42 and quality of life 1146-54
eosinophilic, bronchoalveolar lavage cells 743-9 tuberculosis in adults in Scotland 1289-94
Pseudomonas putida with mucoid phenotype 693-7 (CR) vasculitis with anti-Jo-1 antibodies 986-8 (CR)
pneumothorax veno-occlusive disease complicating Felty’s syndrome
drainage with i.v. catheter 961—2 (CR) 1089-91 (CR)
persistent air leak 767-61 diagnosis 979-83 C(R)
in pulmonary tuberculosis 1269-73 pulse oximetry
recurrent spontaneous, in bronchial asthma 887-9 (CR) COPD screening for long-term domiciliary oxygen need
spontaneous, delayed referral reduction of success in 1265-8
video-assisted thoracoscopy 246-9 at fibreoptic bronchoscopy in local anaesthesia 532-7
impact on smoking behaviour in young people 1132-6 in smokers 989-90 (L)
polymyositis and pulmonary fibrosis in Jo—1 syndrome
1167-9 (CR) quality of life
positive end-expiratory pressure effect in cardiac surgery analysis in sarcoidosis 750-6
858-62 in COPD correlated with lung and muscle function 221-7
prednisolone in acute childhood asthma 541-6 in elderly with COPD 1231-6
protease improvement following increased elastic recoil after lung
damage to epithelial cells in cystic fibrosis sputum 233-40 volume reduction surgery in emphysema 653-8
-inhibitor system Z, alpha,-antitrypsin deficiency risk in measurement in asthma 1207-14
pulmonary emphysema 241-5 pulmonary rehabilitation programme effect on 1146-54
Pseudomonas-derived proteases in cystic fibrosis sputum,
damage to epithelial cells 233-40 re-breathing vs single breath TLCO in COPD 18-24
Pseudomonas putida with mucoid phenotype, pneumonia renal hormonal balance in COPD, hypoxia effect on 1331-6
from 693-7 (CR) respiratory
Pulmo-graph peak flow meter 505-11 decompensation time course in COPD 936-41
pulmonary failure, hypercapnic, secondary to sclerodermic chest wall
adenomatoid malformation presenting as unilobar cysts restriction, non-invasive ventilation in 1170-2 (CR)
in adult 1364-7 (CR) system compliance following thoracoplasty 810-14
aspergillosis in insulin-dependent diabetic 972-5 (CR) symptoms prevalence in Sweden 1337-45
rhabdomyolysis and bacterial pneumonia 359-62 (CR) habits, social processes in development 150—5
rhinitis eosinophil and monocyte counts related to lung function
chronic non-asthmatic, hypo-osmolar aerosol induction and 63-69
of hyperventilation in 9-13 and interleukin-8 secretion by alveolar macrophages
leukotriene antagonism in 795-809 922-7
macrophage phenotype in sputum 415-20
salbutamol by mother, socioeconomic status and birth order effect
‘as required’, vs salmeterol in asthmatic children 292-9 on childhood allergy 1237-44
bronchoprotection from new powder inhaler 578-83 passive, effect on lung function in primary school chil-
early reversibility and bronchodilation prediction after dren 928-35
salmeterol in COPD 1012-16 pulse oximetry 989-90 (L)
effects on bronchodilator responses in COPD 279-82 snoring, Breathe Right™ effects on 1076-8
in Turbuhaler™ for acute asthma 167-72 socioeconomic status and maternal smoking effect on child-
and salmeterol in asthma, cardiorespiratory response to hood allergy 1237-44
submaximal exercise following 1053-8 spirometer, electronic hand-held 1177-80
use recording on diary card compared to compliance spirometric
monitor recording 1188-90 measurement selection 498-504
via Turbuhaler® vs metered-dose inhaler in asthma reference equations for older adults 914-21
325-30 splenic biopsy, salmonella empyema following 968-9 (CR)
vs formoterol onset of action in reversing methacholine- steroid
induced bronchoconstriction 1346-51 -dependent asthma, management with methotrexate
salmeterol 1059-65
and salbutamol in asthma, cardiorespiratory response to inhaled, improved delivery with hydrofluoroalkane-134a
submaximal exercise following 1053-8 (S.A.) 3-8
early reversibility and bronchodilation prediction in topical, effect on nasal nitric oxide production in peren-
COPD after 1012-16 nial allergic rhinitis 558-61
trials in asthma 777-82 see also corticosteroid
vs ‘as required’ salbutamol in asthmatic children 292-9 swine house dust and levels of IL-1f and IL-1 receptor
vs formoterol in reversible obstructive airways disease antagonist in peripheral blood 1022-7
836-42 systemic sclerosis, interstitial lung disease in 1295-301
vs ipratropium bromide effects on exercise performance
and breathlessness in COPD 1116-21 T cell
vs oxitropium bromide as bronchodilators in COPD lymphocytopenia, CD4*, miliary TB causing acute
354-7 (SR) respiratory failure in 977—9 (CR)
vs slow-release theophylline for long-term therapy in receptor subsets of lymphocytes in bronchoalveolar
asthma 683-90 lavage in pulmonary TB 408-14
vs theophylline in asthma 256-63 in sarcoidosis 126-239
xinafoate in asthma 1302-4 (SR) Takayasu’s arteritis, pulmonary infarction revealing 969-71
salmonella empyema following splenic biopsy 968-9 (CR) (CR)
sarcoidosis talc pleurodesis, apical pleural mass development following
clinical manifestation, staging and therapy 140-9 histori- 358-9 (CR)
cal perspective and immunopathogenesis 126-39 terbutaline
familial, HLA-DQBI and HLA-DPBI genotypes 649-52 effects on phagocytosis in alveolar macrophages 162-6
quality of life analysis 750-6 q.i.d. compared to formoterol b.i.d. via Turbuhaler“
recurrent venous obstruction 785-9 (CR) 1040-5
sclerodermic chest wall restriction, non-invasive ventilation theophylline
in hypercapnic respiratory failure secondary to 1170-2 vs salmeterol in asthma 256-63
(CR) vs slow-release salmeterol for long-term therapy in
sclerosis, amyotrophic lateral, long-term mechanical venti- asthma 683-90
lation 438-41 thoracic gas compression profile during forced expiration in
serum markers for sarcoidosis 140-9 asthma and health 173-7
single breath thoracoplasty, total respiratory system compliance 810-14
transfer factor measurement 628-32 thoracoscopy
vs re-breathing 7LCO in COPD 18-24 results and complications 228—32
skin changes, effects of beclomethasone dipropionate com- video-assisted, delayed referral reduction of success in
parison with budesonide (S.B.) 2-45 spontaneous pneumothorax 246-9
sleep apnoea see obstructive sleep apnoea thymic carcinoid with mucinous stroma 880-2 (CR)
sleep tobramycin, i.v., hypomagnesaemic tetany in cystic fibrosis
-disordered breathing comparison in Asians and 602-4 (CR)
Caucasians 843-8 tracheal obstruction and pleomorphic adenoma 889-91
recording, diurnal ambulatory, in obstructive sleep (CR)
apnoea syndrome 216-20 transfer factor for CO, single breath vs re-breathing, in
smoking COPD 18-24
behaviour, effect of pneumothorax in young people tuberculosis
1132-6 case-finding in Australia, chest radiography and 198-202
in cattle, human implications 990-1 (L) ventilation
contact tracing in low-incident area 1127-31 domiciliary non-invasive, in elderly patients 1311—20
Cushing’s disease and 604-6 (CR) during dialysis in pressure support ventilation 534—40
miliary, causing acute respiratory failure in idiopathic in ICU, outcome in COPD 156-61
CD4° T-lymphocytopenia 977-9 (CR) long-term mechanical, in amyotrophic lateral sclerosis
pleurisy, pleural biopsy vs pleuroscopy 488-92 438-4]
pro-inflammatory cytokine compartmentalization nocturnal non-invasive, COPD outcome following
14-17 1215-22
pulmonary, in adults in Scotland 1289-94 non-invasive, in hypercapnic respiratory failure second-
pneumothorax in 1269-73 ary to sclerodermic chest wall restriction 1170-2
radiographic spectrum 493-7 (CR)
T cell receptor subsets of lymphocytes in bronchoal- Vitalograph"™ 2110 evaiuation 1177-80
veolar lavage in von Willebrand factor antigen plasma levels in acute bron-
single pleural nodule in minor fissure 783-91 (CR) chitis and normal population 395-400
smear-negative pulmonary, rapid diagnosis via fibreoptic
bronchoscopy 815-19
Turbuhaler “ Wright Pocket meter 505-11
for beta,-agonists in acute asthma 167-72
low-dose formoterol b.i.d. compared to terbutaline q.i.d.
via 1040-5 Xanthomonas maltophila respiratory infection therapy in
vs Diskus 105—10 cystic fibrosis 363-4 (CR)
vs metered-dose inhaler in asthma, salbutamol in 325-30